MK-6837 Phase 1 Solid Tumor Trial (NCT06460961)

MK-6837 Phase 1 Solid Tumor Trial (NCT06460961)

Overview

MK-6837 Phase 1 Solid Tumor Trial (NCT06460961)

Overview

MK-6837-001 is a Phase 1 open-label, multicenter clinical trial evaluating MK-6837, an investigational agent developed by Merck Sharp & Dohme LLC, as both monotherapy and in combination with other anticancer therapies in participants with advanced or metastatic solid tumors["@clinicaltrials2024"].

The trial is designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of MK-6837. Given the study's keywords referencing PD-1/PD-L1 pathways, MK-6837 likely functions as an immunotherapeutic agent — possibly a small molecule modulator of the PD-1/PD-L1 axis or a novel checkpoint pathway inhibitor["@merckpipeline"].

Trial Details

| Attribute | Value |
|-----------|-------|
| Phase | Phase 1 |
| Status | Active, not recruiting (verified December 2025) |
| Sponsor | Merck Sharp & Dohme LLC |
| NCT Number | NCT06460961 |
| Study ID | MK-6837-001 / 6837-001 |
| Enrollment | 168 participants (estimated) |
| Age Range | 18 years and older |
| Sex | All |
| Start Date | July 14, 2024 |
| Primary Completion | July 13, 2027 (estimated) |
| Completion Date | July 13, 2027 (estimated) |
| Study Type | Interventional |
| Allocation | Non-randomized |
| Intervention Model | Parallel |
| Masking | None (open-label) |
| Primary Purpose | Treatment |

Study Design

• Design: Open-label, dose-escalation and dose-expansion Phase 1
• Arms: Parallel design with monotherapy and combination therapy cohorts
• Treatment Cycles: Each cycle is 21 days
• Duration: Up to approximately 35 months of treatment

Mechanism of Action

MK-6837 Pharmacology

MK-6837 is an investigational agent from Merck's oncology pipeline. Based on the study's inclusion of PD-1/PD-L1/PD-L2 keywords, MK-6837 likely targets the programmed cell death protein 1 (PD-1) pathway or a related immunomodulatory mechanism.

The PD-1/PD-L1 axis is a critical immune checkpoint:

• PD-1 (Programmed Cell Death Protein 1) is an inhibitory receptor expressed on activated T cells
• PD-L1 (Programmed Death-Ligand 1) is a transmembrane protein often upregulated on tumor cells and antigen-presenting cells
• When PD-1 binds PD-L1, it suppresses T cell activation and enables tumor immune evasion

Rationale for Solid Tumor Targeting

Advanced and metastatic solid tumors frequently exploit PD-L1 upregulation to evade immune detection. By targeting this pathway, MK-6837 aims to:

Monotherapy vs. Combination Therapy

The trial studies MK-6837 both alone and in combination with other agents, reflecting the clinical reality that:

• Combination approaches can overcome resistance mechanisms
• Immunotherapy + chemotherapy/radiation can enhance antigen release
• Sequential or concurrent targeting of multiple pathways may improve outcomes

Eligibility Criteria

Key Inclusion Criteria

• Histologically or cytologically confirmed solid tumor by pathology report that is advanced or metastatic
• Human Immunodeficiency Virus (HIV)-infected participants must have well-controlled HIV on Antiretroviral Therapy (ART)
• Hepatitis B Surface Antigen (HBsAg) positive participants are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation
• Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable at screening

Key Exclusion Criteria

• Has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from any adverse events due to cancer therapeutics administered more than 4 weeks earlier
• History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
• Clinically significant cardiovascular disease
• HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
• Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention
• Prior immunotherapy discontinued due to Grade 3 or higher immune-related adverse event (except endocrine disorders treatable with replacement therapy) or due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
• Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities requiring corticosteroids
• Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
• Known additional malignancy that is progressing or required active treatment within the past 2 years
• Known active Central Nervous System (CNS) metastases and/or carcinomatous meningitis
• Active autoimmune disease that has required systemic treatment in the past 2 years (except replacement therapy)
• History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• Active infection requiring systemic therapy
• History of allogeneic tissue/solid organ transplant

Primary Outcomes

Dose-Limiting Toxicity (DLT) Assessment

Primary Endpoint: Number of participants who experience one or more dose-limiting toxicities (DLTs)[@clinicaltrials2024].

The following events are considered DLTs unless clearly due to underlying disease or extraneous causes:

• Grade 4 neutropenia lasting >7 days
• Grade 3 or higher thrombocytopenia associated with clinically significant bleeding (regardless of duration)
• All Grade 3 or higher nonhematologic toxicities (with specified exceptions)
• Any abnormality that results in drug-induced liver injury
• Febrile neutropenia Grade 3 or 4
• Prolonged delay (>2 weeks) in initiating treatment after the first 21 days due to intervention-related toxicity
• Any intervention-related toxicity that causes the participant to discontinue intervention during the first 21 days
• Grade 5 toxicity

This DLT assessment is standard in Phase 1 oncology trials to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).

Safety Profile

Secondary Endpoints (Safety):

• Number of participants who experience one or more adverse events (AEs)
• Number of participants who discontinue study intervention due to an AE

Study Design Details

Treatment Arms

The trial employs a parallel design with multiple arms:

| Arm | Description | Status |
|-----|-------------|--------|
| Experimental (Monotherapy) | MK-6837 alone | Active |
| Experimental (Combination) | MK-6837 + other anticancer agent(s) | Active |

Dose Escalation Strategy

Phase 1 oncology trials typically use dose-escalation designs (e.g., 3+3, rolling-six, or Bayesian designs) to identify the optimal dose. The monotherapy arm likely serves as the lead-in for dose determination, followed by expansion cohorts and combination arms.

Pharmacokinetic/Pharmacodynamic Objectives

Standard Phase 1 objectives include:

• Characterizing MK-6837 plasma pharmacokinetics (Cmax, AUC, half-life, clearance)
• Assessing target engagement biomarkers
• Evaluating preliminary antitumor activity (objective response rate, disease control rate)

Scientific Rationale

Why Target PD-1/PD-L1 in Solid Tumors

The PD-1/PD-L1 axis is one of the most validated targets in modern oncology:

• PD-L1 expression is a predictive biomarker for response to checkpoint inhibitors
• Blockade can produce durable responses in multiple tumor types (melanoma, lung, bladder, kidney, etc.)
• Combination with chemotherapy, radiation, or targeted therapy can enhance efficacy
• Small molecule inhibitors may offer advantages over antibodies (oral bioavailability, improved tumor penetration, lower immunogenicity)

Novel Agent Positioning

MK-6837 represents Merck's continued investment in immunotherapy, building on the success of pembrolizumab (Keytruda). Potential differentiators include:

• Novel mechanism beyond existing checkpoint inhibitors
• Small molecule format enabling different dosing and scheduling
• Possible activity in tumors resistant to existing checkpoint blockade

Relationship to Neurodegeneration

While this trial is an oncology study, immune checkpoint pathways have relevance in neurodegenerative disease research:

• PD-1/PD-L1 in Neuroinflammation: The PD-1 pathway modulates microglial activation and neuroimmune responses. Preclinical studies have explored whether checkpoint modulation affects neuroinflammation in Alzheimer's and Parkinson's disease models[@sah2021].
• Cancer-Neurodegeneration Paradox: Epidemiologic studies have noted inverse associations between certain cancers and neurodegenerative disease risk, possibly involving shared signaling pathways.
• Immune System Cross-Talk: Understanding immunomodulatory mechanisms has implications beyond oncology.

Merck Oncology Pipeline

Merck (MSD outside the US) has one of the most established oncology portfolios in the industry:

| Drug | Mechanism | Indication |
|------|-----------|-----------|
| Pembrolizumab (Keytruda) | Anti-PD-1 mAb | Multiple solid tumors |
| MK-2870 (SKB264) | TROP2 ADC | Solid tumors |
| MK-1084 | PD-L1/TGF-beta bifunctional | Solid tumors |
| MK-6837 | Novel immunotherapy | Advanced solid tumors |

MK-6837 represents Merck's next wave of immunomodulatory agents beyond the established anti-PD-1 antibody franchise.

Related Pages

• [PD-1/PD-L1 Checkpoint Inhibitors in Cancer Immunotherapy](/mechanisms/pd1-pdl1-checkpoint-inhibition)
• [Cancer Immunotherapy: Checkpoint Inhibition](/mechanisms/cancer-immunotherapy-checkpoint-inhibition)
• [Cancer Immunotherapy](/mechanisms/cancer-immunotherapy)
• [Merck Sharp & Dohme LLC](/organizations/merck-sharp-dohme)
• [Immunotherapy for Neurodegenerative Diseases](/therapeutics/immunotherapy-neurodegeneration)
• [MK-1167 Phase 2 AD Trial (NCT06721156)](/clinical-trials/mk-1167-merck-phase-2-ad-nct06721156)

References